Targets › CD3D
11 programs from 8 companies in 358 trials: 209 Phase 2, 93 Phase 1, 53 Phase 3, 3 Phase 4; Oncology, Immunology, Metabolic and endocrine; next expected readout Jan 2027.
Part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential role in adaptive immune response. When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD247/CD3Z. All CD3 chains contain immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic domain. (UniProt, P04234)
Open in Phaseline: the race on CD3D, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Pfizer | Elranatamab T cell surface glycoprotein CD3 binding agent; Tumor necrosis factor receptor superfamily member 17 binding agent | CD3E, CD3G, CD3D, TNFRSF17 | Phase 4 | Multiple Myeloma; Multiple Myeloma, Newly Diagnosed; Relapsed Refractory Multiple Myeloma (RRMM); Refractory Multiple Myeloma … | May 2027 |
| Roche | Glofitamab B-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agent | MS4A1, CD3E, CD3G, CD3D | Phase 3 | Lymphoma; Large B-Cell Lymphoma; Diffuse Large B-cell Lymphoma; Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma … | Jan 2027 |
| Roche | Mosunetuzumab T cell surface glycoprotein CD3 binding agent; B-lymphocyte antigen CD20 binding agent | CD3E, CD3G, CD3D, MS4A1 | Phase 3 | Non-Hodgkin Lymphoma; Relapsed or Refractory Follicular Lymphoma; Lupus; B-cell Non-Hodgkin Lymphoma … | Feb 2027 |
| Genmab | Epcoritamab B-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agent | MS4A1, CD3E, CD3G, CD3D | Phase 3 | Diffuse Large B-Cell Lymphoma; Diffuse Large B-cell Lymphoma; Follicular Lymphoma (FL); Non-Hodgkin Lymphoma … | Mar 2027 |
| Johnson & Johnson (Janssen) | Talquetamab T cell surface glycoprotein CD3 binding agent; G-protein coupled receptor family C group 5 member D binding agent | CD3E, CD3G, CD3D, GPRC5D | Phase 3 | Multiple Myeloma; Hematological Malignancies; Relapsed/ Refractory Multiple Myeloma; Multiple Myeloma (MM) … | Apr 2027 |
| Johnson & Johnson (Janssen) | Teclistamab T cell surface glycoprotein CD3 binding agent; Tumor necrosis factor receptor superfamily member 17 binding agent | CD3E, CD3G, CD3D, TNFRSF17 | Phase 3 | Multiple Myeloma; Hematological Malignancies; Relapsed/ Refractory Multiple Myeloma; Multiple Myeloma (MM) … | Apr 2027 |
| Amgen | Tarlatamab T cell surface glycoprotein CD3 binding agent; Delta-like protein 3 binding agent | CD3E, CD3G, CD3D, DLL3 | Phase 3 | Small Cell Lung Cancer; Small Cell Lung Cancer (SCLC); Small-cell Lung Cancer; Extensive-Stage Small-Cell Lung Cancer … | Apr 2027 |
| Amgen | Blinatumomab T cell surface glycoprotein CD3 cross-linking agent; B-lymphocyte antigen CD19 cross-linking agent | CD3E, CD3G, CD3D, CD19 | Phase 3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL); B Precursor Acute Lymphoblastic Leukemia; Systemic Lupus Erythematosus; B Cell Precursor Acute Lymphoblastic Leukemia … | Oct 2027 |
| Regeneron Pharmaceuticals | Odronextamab B-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agent | MS4A1, CD3E, CD3G, CD3D | Phase 3 | Follicular Lymphoma (FL); Diffuse Large B-cell Lymphoma (DLBCL); B-Cell Non-Hodgkin Lymphoma (B-NHL); Relapsed/Refractory Follicular Lymphoma … | Feb 2028 |
| Tiziana Life Sciences | Foralumab (TZLS-401) T cell surface glycoprotein CD3 inhibitor | CD3E, CD3G, CD3D | Phase 2 | Non-Active Secondary Progressive Multiple Sclerosis; Secondary Progressive Multiple Sclerosis; Multiple System Atrophy; Dementia | Apr 2027 |
| Children's Oncology Group | Flotetuzumab Interleukin-3 receptor subunit alpha binding agent; T cell surface glycoprotein CD3 binding agent | IL3RA, CD3E, CD3G, CD3D | Phase 1 | Recurrent Acute Myeloid Leukemia | Mar 2027 |
Multiple Myeloma (56) Follicular Lymphoma (13) Acute Lymphoblastic Leukemia (13) Diffuse Large B-Cell Lymphoma (8) Lymphoma (7) Large B-cell Lymphoma (7) B Acute Lymphoblastic Leukemia (6) Recurrent Diffuse Large B-Cell Lymphoma (5) Multiple Myeloma (MM) (5) Non-Hodgkin Lymphoma (5) Mantle Cell Lymphoma (5) B-cell Acute Lymphoblastic Leukemia (5)
mixed (9), antibody (2)
Amgen (2) Roche (2) Johnson & Johnson (Janssen) (2) Regeneron Pharmaceuticals (1) Tiziana Life Sciences (1) Pfizer (1) Genmab (1) Children's Oncology Group (1)
CD3E (11) CD3G (11) MS4A1 (4) TNFRSF17 (2) DLL3 (1) GPRC5D (1) CD19 (1) IL3RA (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.